cKITxCD16axCD47 fusion protein therapeutic - Molecular Partners
Alternative Names: cKITxCD16axCD47 Switch-DARPinLatest Information Update: 01 Feb 2024
At a glance
- Originator Molecular Partners AG
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action CD47 antigen inhibitors; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Acute myeloid leukaemia